Safety, Tolerability, and Efficacy of Everolimus in De Novo Liver Transplant Recipients: 12- and 36-Month Results
Gary Levy(University Health Network), Lutz Fischer(Unknown), David Mayer(Queen Elizabeth Hospital Birmingham), Alan N. Langnas(University of Nebraska Medical Center), M. J. H. Sloof, Björn Nashan(Medizinische Hochschule Hannover), Richard B. Freeman(Harvard University Press), Didier Samuel(Hôpital Paul-Brousse), Michaël Abécassis(University of Arizona), Heinz Schmidli(Novartis (Switzerland)), Yvon Calmus(Hôpital Cochin), J. Klempnauer(Medizinische Hochschule Hannover), Xavier Rogiers(Ghent University Hospital), Elizabeth Tuttle‐Newhall(Duke Medical Center), Jeffrey D. Punch(University of Michigan), John P. Roberts(University of California, San Francisco)
Cited by 140
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival
|Hepatology|2001|2.3k
The International Position on Laparoscopic Liver Surgery
|Annals of Surgery|2009|1.5k
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors
|Liver Transplantation|2010|1.2k